<DOC>
	<DOCNO>NCT00319618</DOCNO>
	<brief_summary>The purpose study determine combination therapy weekly Taxotere™ Iressa™ increase objective response measurable leasions metastatic breast cancer</brief_summary>
	<brief_title>Combination Weekly Taxotere™ With Iressa™ /Placebo Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm mammary carcinoma prior taxane chemotherapy metastatic disease prior treatment tyrosine kinase inhibitor inhibit EGF receptor . Prior hormone treatment one type anthracycline base treatment regimen without taxane metastatic disease allow prior inclusion . If patient treat adjuvant neoadjuvant setting taxanes , inclusion allow first cycle trial medication start 12 month last course adjuvant treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>